Oragenics (NYSEAMERICAN:OGEN) Stock Crosses Above Two Hundred Day Moving Average of $0.00
Oragenics (NYSEAMERICAN:OGEN) Stock Crosses Above Two Hundred Day Moving Average of $0.00
Shares of Oragenics, Inc. (NYSEAMERICAN:OGEN – Get Rating) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $2.95. Oragenics shares last traded at $2.73, with a volume of 8,844 shares trading hands.
Oragenics, Inc.（纽约证券交易所代码：OGEN — GET Rating）的股价在周五的交易中突破了其两百天移动平均线。该股的两百天移动平均线为0.00美元，交易价格高达2.95美元。Oragenics股票最后一次交易价格为2.73美元，交易量为8,844股。
Oragenics Stock Down 1.4 %
Oragenics 股票下跌 1.4%
The company has a market cap of $5.35 million, a P/E ratio of -21.00 and a beta of 0.19.
该公司的市值为535万美元，市盈率为-21.00，beta值为0.19。
Hedge Funds Weigh In On Oragenics
对冲基金对Oragenics大加赞成
Institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp boosted its stake in Oragenics by 8.1% in the first quarter. State Street Corp now owns 495,563 shares of the biotechnology company's stock worth $171,000 after purchasing an additional 37,338 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Oragenics by 116.5% during the second quarter. Renaissance Technologies LLC now owns 209,600 shares of the biotechnology company's stock worth $73,000 after acquiring an additional 112,800 shares during the last quarter. Finally, Millennium Management LLC raised its position in shares of Oragenics by 591.6% during the second quarter. Millennium Management LLC now owns 128,733 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 110,119 shares during the last quarter. Institutional investors and hedge funds own 9.31% of the company's stock.
机构投资者和对冲基金最近买入和卖出了该公司的股票。State Street Corp在第一季度将其在Oragenics的股份增加了8.1％。State Street Corp在上个季度又购买了37,338股股票后，现在拥有这家生物技术公司495,563股股票，价值17.1万美元。Renaissance Technologies LLC在第二季度将其在Oragenics的股票头寸提高了116.5％。Renaissance Technologies LLC在上个季度又收购了112,800股股票后，现在拥有这家生物技术公司的209,600股股票，价值73,000美元。最后，Millennium Management LLC在第二季度将其在Oragenics的股票头寸提高了591.6％。Millennium Management LLC在上个季度又收购了110,119股股票后，现在拥有这家生物技术公司的128,733股股票，价值45,000美元。机构投资者和对冲基金拥有该公司9.31％的股票。
Oragenics Company Profile
Oragenics 公司简介
(Get Rating)
（获取评分）
Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
Oragenics, Inc在美国开发用于传染病的抗生素。该公司参与NT-CoV-2-1（一种提供新型严重急性呼吸综合征冠状病毒免疫力的鼻内候选疫苗）的开发和商业化；以及提供对新型严重急性呼吸综合征冠状病毒免疫的肌肉注射候选疫苗Terra CoV-2。
Featured Articles
精选文章
- Get a free copy of the StockNews.com research report on Oragenics (OGEN)
- Dividend King Genuine Parts Company Upgraded On Profit Guidance
- The Bottom Is In For Accenture
- 11 Best Consumer Discretionary Stocks of 2023
- 10 Best Consumer Discretionary ETFs
- 5 Best Dividend Capture Stocks
- 免费获取 StockNews.com 关于 Oragenics (OGEN) 的研究报告
- Diversion King 原装零件公司在利润指导上
- 埃森哲已经触底了
- 2023 年 11 只最佳非必需消费品股
- 十大最佳非必需消费品ETF
- 5 只最佳股息捕获股票
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Oragenics Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Oragenics及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。